The current financial score of Pacira Biosciences Inc is 8.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 192.40M, representing a year-over-year increase of 6.24%, while its net profit experienced a year-over-year increase of 196.00%.
The current valuation score of Pacira Biosciences Inc is 8.16. Its current P/E ratio is 194.42, which is 20.24% below the recent high of 233.78 and 294.18% above the recent low of -377.53.
The current earnings forecast score of Pacira Biosciences Inc is 7.00. The average price target is 28.86, with a high of 38.00 and a low of 23.00.
The current price momentum score of Pacira Biosciences Inc is 3.35. Currently, the stock price is trading between the resistance level at 26.38 and the support level at 23.12, making it suitable for range-bound swing trading.
The current institutional shareholding score of Pacira Biosciences Inc is 10.00. The latest institutional shareholding proportion is 122.53%, representing a quarter-over-quarter increase of 1.68%. The largest institutional shareholder is James Simons, holding a total of 1.73M shares, representing 0.06% of shares outstanding, with 28.12% decrease in holdings.
The current risk assessment score of Pacira Biosciences Inc is 8.00. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.